Related Experiment Video

Updated: Jan 20, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.0K

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients

Niki Karachaliou1, Jordi Codony-Servat2, Jillian Wilhelmina Paulina Bracht2

  • 1Global Clinical Development, Merck Healthcare KGaA , Darmstadt , Germany.

Expert Review of Respiratory Medicine
|August 15, 2019
PubMed

Insights

Resistance to EGFR tyrosine kinase inhibitors (TKIs) is a major challenge in treating lung adenocarcinoma. Understanding resistance mechanisms is crucial for developing effective therapies for EGFR-mutant lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) mutations are key drivers in lung adenocarcinoma, particularly in Caucasian patients (10-15%).
  • EGFR mutations predict a positive response to EGFR tyrosine kinase inhibitors (TKIs) like erlotinib.
  • Tumor cells develop resistance to TKIs through compensatory signaling pathways, limiting treatment efficacy.

Purpose of the Study:

  • To review mechanisms of resistance to first-generation EGFR TKIs, specifically erlotinib.
  • To summarize recent findings (last 10 years) in EGFR-mutant lung cancer resistance.
  • To highlight unmet needs in combination therapies for resistant EGFR-mutant lung cancer.

Main Methods:

  • Literature review focusing on EGFR-mutant lung cancer.
  • Analysis of resistance mechanisms to first- and second-generation EGFR TKIs.
  • Summary of recent advancements and approved therapies.

Main Results:

  • Several mechanisms of resistance to EGFR TKIs have been identified.
  • No combination therapies are currently approved for EGFR-mutant lung cancer at the time of resistance.
  • Osimertinib, a third-generation EGFR TKI, is approved for T790M-mediated resistance.

Conclusions:

  • Understanding resistance mechanisms is critical for personalized treatment strategies.
  • Development of effective combination therapies for EGFR-mutant lung cancer remains an unmet need.
  • Targeted therapies, like osimertinib, show promise for specific resistance mutations.
Keywords:
Erlotinibcombinatory therapiesresistance

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.1K
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.4K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
5.7K
Resistance and Conductance01:25

Resistance and Conductance

A conductor's DC resistance at a given temperature is influenced by its resistivity, length, and cross-sectional area. Resistivity is an inherent property of the conductor material, with annealed copper serving as the international standard for measurement. For instance, the resistivity of hard-drawn aluminum at 20 degrees Celsius is 61% of the standard conductivity of annealed copper.
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
492
Equivalent Resistance01:16

Equivalent Resistance

In circuit analysis, situations often arise where resistors are neither in series nor parallel configurations. To tackle such scenarios, three-terminal equivalent networks like the wye (Y) (Figure 1 (a)) or tee (T) and delta (Δ) (Figure 1 (b)) or pi (π) networks come into play. These networks offer versatile solutions and are frequently encountered in various applications, including three-phase electrical systems, electrical filters, and matching networks.
939